TNGX Stock Analysis: Buy, Sell, or Hold?
TNGX - Tango Therapeutics, Inc.
$28.80
0.41 (1.44%)
▲
5d:
-10.45%
30d:
+42.29%
90d:
+47.84%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When TNGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TNGX is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TNGX is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TNGX is currently trading at $28.80, which is considered slightly high relative to its 30-day fair value range of $20.12 to $29.78.
Technical Outlook: Technically, TNGX is in a strong uptrend. Immediate support is located at $27.65, while resistance sits at $34.39.
Market Sentiment: TNGX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.45 (+42.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TNGX is in a strong uptrend. Immediate support is located at $27.65, while resistance sits at $34.39.
Market Sentiment: TNGX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.45 (+42.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$20.12 -
$29.78
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
78.9%
Protect Your Profits
Holding TNGX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.5% below Wall St target ($40.45)
- WARNING: Recommendation downgraded due to -10.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$20.12 -
$29.78
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$27.65
Resistance Level
$34.39
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.12
Wall Street Target
$40.45
(+42.5%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-188.2%
Share & Embed Analysis
Last updated: June 24, 2026 10:43 AM ET
Data refreshes hourly during market hours. Next update: 11:43 AM
Data refreshes hourly during market hours. Next update: 11:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Adam Crystal
SELL
38460 shares
2026-04-15
Adam Crystal
SELL
27000 shares
2026-04-01
Adam Crystal
SELL
12000 shares
2026-03-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced TNGX Option Strategies
Professional options setups generated by AI based on today's TNGX price and gamma walls.
